AHK-Cu vs Survodutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
AHK-Cu
AHK-Cu (Copper Tripeptide-3, Alanine-Histidine-Lysine Copper) is a copper peptide similar to GHK-Cu but with different properties. It's used for hair growth and skin rejuvenation applications.
Full details →Survodutide
Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. It is being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and obesity. Survodutide's glucagon receptor activation promotes hepatic fat mobilization, making it uniquely suited for liver-related metabolic conditions.
Full details →Side-by-Side Comparison
| Aspect | AHK-Cu | Survodutide |
|---|---|---|
| Mechanism | The copper-binding tripeptide stimulates collagen synthesis and may promote hair follicle enlargement. Works similarly to GHK-Cu but may have distinct receptor interactions. | Survodutide activates both GLP-1 and glucagon receptors. The GLP-1 component provides appetite suppression, glucose-dependent insulin secretion, and delayed gastric emptying. The glucagon component drives hepatic fat oxidation, increases energy expenditure, and promotes lipolysis. This dual mechanism is particularly effective for MASH, where hepatic fat accumulation is the core pathology. Unlike tirzepatide (which targets GIP/GLP-1), survodutide targets glucagon/GLP-1 — a different receptor combination optimized for liver and metabolic outcomes. |
| Typical Dosage | Topical: 0.5-2% concentration in serums for skin or scalp applications. Often combined with other growth factors for hair formulations. | Phase 2 MASH trial: escalated to 2.4 mg, 4.8 mg, or 6.0 mg weekly. Phase 2b obesity trial: up to 6.0 mg weekly. Dose escalation over 16-20 weeks to manage GI tolerability. Final approved dosing not yet established — Phase 3 trials ongoing. |
| Administration | Topical application to skin or scalp. Can be used with microneedling for enhanced penetration. May cause temporary blue-green tint at high concentrations. | Subcutaneous injection, once weekly. Phase 3 trials use pre-filled pens. Not yet commercially available. Phase 3 results expected 2026-2027. |
| Side Effects | Generally well-tolerated. May cause skin irritation in sensitive individuals. Temporary discoloration possible. | Phase 2 data: nausea, vomiting, diarrhea (dose-dependent, generally transient). Reduced appetite. Transient increases in heart rate. The GI side effect profile appears similar to other GLP-1 agonists. |
| Best For |
Key Differences
Unique to AHK-Cu:
Unique to Survodutide:
Detailed Analysis
Commonalities
AHK-Cu and Survodutide are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose AHK-Cu for Skin Health & Aesthetics. Choose Survodutide for Weight Loss, Liver Health.
Ready to Learn More?
Looking for trusted sources?